SCHEMBL6933360

SCHEMBL6933360

CCCc1cc(C(=O)c2ccccc2)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.52
PPARA Q07869 1/20 0.52
PTGS1 P23219 2/20 0.51
PTGS2 P35354 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.48
ATM Q13315 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ELANE P08246 4/20 0.48
ALDH1A1 P00352 3/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
KMT2A Q03164 1/20 0.46
CNR2 P34972 1/20 0.46
ACHE P22303 1/20 0.45
LTB4R Q15722 1/20 0.44
SRD5A2 P31213 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24648579 0.92 F10 (0.48) PPARGPPARAPTGS1PTGS2L3MBTL1
SCHEMBL8654136 0.92 HSP90AA1 (0.50) ALDH1A1HPGDCNR2HSP90AA1HSP90AB1
SCHEMBL24648555 0.86 LMNA (0.52) PPARGPPARATDP1ALDH1A1CNR2
SCHEMBL10704144 0.83 AKR1B1 (0.58) PTGS1PTGS2L3MBTL1ATMTDP1
SCHEMBL13114560 0.83 ALDH1A1 (0.53) ALDH1A1RAB9AHPGDMEN1KMT2A
SCHEMBL2003391 0.83 POLB (0.53) PTGS2L3MBTL1ALDH1A1HPGDHSP90AA1
SCHEMBL11356019 0.83 KDM4E (0.54) PPARGPPARAPTGS1PTGS2L3MBTL1
SCHEMBL17179972 0.81 PKM (0.61) PTGS1PTGS2L3MBTL1ATMTDP1
SCHEMBL5973730 0.81 MAPK14 (0.46) PTGS2TDP1ALDH1A1RAB9AHPGD
SCHEMBL9616832 0.80 PKM (0.68) ALDH1A1HPGDMEN1KMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787777-B1 Crown ether amines and methods of use PALL CORPORATION (US) 2023-10-17 US disclosed
EP-0888278-B1 ANTIDIABETIC AGENTS MERCK & CO INC (US) 2003-07-23 EP disclosed
EP-0888278-A4 ANTIDIABETIC AGENTS MERCK & CO INC (US) 1999-06-30 EP disclosed
EP-0888278-A1 ANTIDIABETIC AGENTS Merck & Co., Inc. (US) 1999-01-07 EP disclosed
WO-1997028115-A1 ANTIDIABETIC AGENTS MERCK & CO., INC. (US) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787777-B1 Crown ether amines and methods of use H1-2, H1-0, CNR1 PPARG 3926/4885PPARA 4216/4885PTGS1 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.